235 related articles for article (PubMed ID: 30915997)
21. Mechanisms of opioid-induced respiratory depression.
Baldo BA; Rose MA
Arch Toxicol; 2022 Aug; 96(8):2247-2260. PubMed ID: 35471232
[TBL] [Abstract][Full Text] [Related]
22. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
Freye E; Neruda B; Smith OW
Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
[TBL] [Abstract][Full Text] [Related]
23. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study.
Olofsen E; van Dorp E; Teppema L; Aarts L; Smith TW; Dahan A; Sarton E
Anesthesiology; 2010 Jun; 112(6):1417-27. PubMed ID: 20461002
[TBL] [Abstract][Full Text] [Related]
24. Risk predictors of opioid-induced critical respiratory events in children: naloxone use as a quality measure of opioid safety.
Chidambaran V; Olbrecht V; Hossain M; Sadhasivam S; Rose J; Meyer MJ
Pain Med; 2014 Dec; 15(12):2139-49. PubMed ID: 25319840
[TBL] [Abstract][Full Text] [Related]
25. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal.
Lewanowitsch T; Irvine RJ
Eur J Pharmacol; 2002 Jun; 445(1-2):61-7. PubMed ID: 12065195
[TBL] [Abstract][Full Text] [Related]
26. Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel
Gerak LR; Maguire DR; Woods JH; Husbands SM; Disney A; France CP
J Pharmacol Exp Ther; 2019 Feb; 368(2):229-236. PubMed ID: 30463875
[TBL] [Abstract][Full Text] [Related]
27. Novel Oral Nanoparticle Formulation of Sustained Release Naloxone with Mild Withdrawal Symptoms in Mice.
Madison CA; Arora M; Kumar MNVR; Eitan S
ACS Chem Neurosci; 2020 Jul; 11(13):1955-1964. PubMed ID: 32491828
[TBL] [Abstract][Full Text] [Related]
28. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia.
Oertel BG; Felden L; Tran PV; Bradshaw MH; Angst MS; Schmidt H; Johnson S; Greer JJ; Geisslinger G; Varney MA; Lötsch J
Clin Pharmacol Ther; 2010 Feb; 87(2):204-11. PubMed ID: 19907420
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacology of antagonists of narcotic-induced respiratory depression. A brief review.
Bowdle TA
Acute Care; 1988; 12 Suppl 1():70-6. PubMed ID: 3278495
[TBL] [Abstract][Full Text] [Related]
30. Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
Wilhelm JA; Veng-Pedersen P; Zakszewski TB; Osifchin E; Waters SJ
Int J Clin Pharmacol Ther; 1995 Oct; 33(10):540-5. PubMed ID: 8574503
[TBL] [Abstract][Full Text] [Related]
31. Naloxonazine antagonism of levorphanol-induced antinociception and respiratory depression in rhesus monkeys.
Gatch MB; Liguori A; Negus SS; Mello NK; Bergman J
Eur J Pharmacol; 1996 Feb; 298(1):31-6. PubMed ID: 8867916
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.
Zamani N; Buckley NA; Hassanian-Moghaddam H
Crit Care; 2020 Feb; 24(1):44. PubMed ID: 32033582
[TBL] [Abstract][Full Text] [Related]
33. Neuraxial morphine and respiratory depression: finding the right balance.
Sultan P; Gutierrez MC; Carvalho B
Drugs; 2011 Oct; 71(14):1807-19. PubMed ID: 21942973
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature.
Martini C; Olofsen E; Yassen A; Aarts L; Dahan A
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):719-28. PubMed ID: 22111858
[TBL] [Abstract][Full Text] [Related]
35. Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.
German C; Pilvankar M; Przekwas A
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):513-529. PubMed ID: 31396799
[TBL] [Abstract][Full Text] [Related]
36. Opioid-induced respiratory depression in paediatrics: a review of case reports.
Niesters M; Overdyk F; Smith T; Aarts L; Dahan A
Br J Anaesth; 2013 Feb; 110(2):175-82. PubMed ID: 23248093
[TBL] [Abstract][Full Text] [Related]
37. Understanding and countering opioid-induced respiratory depression.
Bateman JT; Saunders SE; Levitt ES
Br J Pharmacol; 2023 Apr; 180(7):813-828. PubMed ID: 34089181
[TBL] [Abstract][Full Text] [Related]
38. Contribution of the caudal medullary raphe to opioid induced respiratory depression.
Palkovic B; Cook-Snyder D; Callison JJ; Langer TM; Nugent R; Stuth EAE; Zuperku EJ; Stucke AG
Respir Physiol Neurobiol; 2022 May; 299():103855. PubMed ID: 35124284
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the appropriateness of naloxone administration to patients receiving long-term opioid therapy.
Facey C; Brooks D; Boland JW
Hosp Pract (1995); 2016; 44(2):86-91. PubMed ID: 26837434
[TBL] [Abstract][Full Text] [Related]
40. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.
Torralva R; Janowsky A
J Pharmacol Exp Ther; 2019 Nov; 371(2):453-475. PubMed ID: 31492824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
